AAP
ACTU

Arax Advisory Partners’s Actuate Therapeutics ACTU Stock Holding History

Arax Advisory Partners’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
1,310
+1,301
+14,456% +$3.02K ﹤0.01% 4809
2026
Q1 		$25 Buy
+9
New +$37 ﹤0.01% 3699
2025
Q4 		– Sell
-60
Closed -$401 – 4602
2025
Q3 		$401 Buy
+60
New +$435 ﹤0.01% 3389

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Arax Advisory Partners's ACTU Position: Q2 2026 in Review

Arax Advisory Partners increased its Actuate Therapeutics (ACTU) stake by 14,456% in Q2 2026, buying an estimated $3.02K and bringing the position to 1,310 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4809.

Arax Advisory Partners first reported a position in ACTU in Q3 2025 and has held it in 3 quarters since. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Arax Advisory Partners held 1,310 shares of Actuate Therapeutics worth $2K as of Q2 2026.
  • Arax Advisory Partners bought 1,301 Actuate Therapeutics shares in Q2 2026, an estimated $3.02K.
  • Actuate Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4809 holding.
  • Arax Advisory Partners first reported a position in Actuate Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.